Why AI governance is a revenue strategy, not a compliance cost.

1The failure landscape: $547 billion in evidence

In 2025, global enterprises deployed $684 billion in AI initiatives. By year-end, more than $547 billion of that investment had failed to deliver its intended business value — an 80.3% failure rate that is, according to RAND Corporation analysis, more than twice the failure rate of non-AI technology projects.^[1]

These are not abstract statistics. Abandoned AI projects cost enterprises an average of $4.2 million each. Projects completed but failing to deliver value cost $6.8 million while delivering only $1.9 million in realized returns — a negative 72% ROI. Large enterprises lost an average of $7.2 million per failed initiative and abandoned 2.3 initiatives each in 2025 alone.^[2]

Healthcare performs particularly poorly in this landscape: a synthesized failure rate of 78.9% — second highest of any industry sector, behind only financial services.^[2] Only 2% of health systems have deployed AI enterprise-wide. Just 30% operate AI at meaningful scale even in select areas.^[3] This is not for lack of intent: 80% of global healthcare executives expect generative and agentic AI to deliver moderate-to-significant value in 2026.^[3]

The gap between expectation and delivery is not a technology gap. The technology has matured. The governance has not.

MIT's NANDA initiative found that only 5% of enterprise AI pilots achieve rapid revenue acceleration — and that the differentiating factor is not model quality or data volume but organizational structure: clear pre-approval success metrics, formal data readiness processes, and sustained executive accountability.^[4]McKinsey's 2025 analysis corroborates this: organizations reporting significant financial returns from AI are twice as likely to have redesigned end-to-end workflows before selecting modeling techniques.^[5] The pattern is consistent across every dataset. AI fails when governance is absent. AI succeeds when governance is architectural.

2Two sectors, one structural problem

Healthcare and automotive are not obvious comparators. But they share the same fundamental governance challenge: deploying AI in high-consequence environments where failure has direct safety and liability implications, where regulatory frameworks are actively forming, and where the gap between deployment velocity and governance infrastructure is creating systemic risk. The key difference is motivational, not structural.

2.1 The healthcare pull: governance as revenue enabler

CMS's 2026 Medicare Physician Fee Schedule creates, for the first time, explicit reimbursement pathways for AI-enabled services — covering AI-assisted diagnosis, preventive care, and AI-enhanced remote monitoring.^[6] The signal is unambiguous: compliant AI tools generate billable events. Non-compliant tools do not. Bessemer Venture Partners identifies the payment infrastructure, not the technology, as the primary bottleneck for clinical AI adoption, and projects that successful CMS CPT pilot programs will pull commercial payers into equivalent reimbursement structures within 12 to 24 months.^[7]

The consumer market is already moving. When RadNet offered AI-enhanced mammography for $40 out-of-pocket, 36% of 747,000 women chose it — resulting in 43% higher cancer detection rates.^[7] Consumer demand for AI-enabled care is not theoretical. But scaling that demand into institutional revenue requires governance infrastructure that satisfies payer requirements for clinical utility evidence, not merely FDA performance metrics.

2.2 The automotive push: governance as liability defense

In automotive, the equation inverts. The NAIC Model Bulletin has been adopted by 23 states plus the District of Columbia, requiring governance documentation, audit procedures, and accountability frameworks for any AI system used in insurance decisions; 88% of auto insurers use or plan to use AI in underwriting and claims.^[8] The UN Global Regulation on Automated Driving Systems, finalized in January 2026 after a decade of development, establishes international safety-case requirements for AI in vehicle systems.^[9]

The consequence of ungoverned AI here is not a missed revenue opportunity — it is a scalable liability event. A human inspector who misses a defect creates individual liability. An AI system that replicates the same error pattern creates systemic liability: the same error propagated across every inspection the model performed.

Governance documentation is the only legal defense available when AI fails at scale. Without it, systemic liability has no counterweight.

Deloitte's manufacturing analysis finds governance requirements add 20 to 35% to total AI project costs — and classifies this not as overhead but as a non-negotiable condition of deployment.^[10] The calculus is straightforward: governance costs 20–35%. Ungoverned AI failure costs the entire initiative — plus litigation, plus the compounding liability of every instance the system erred before the error was discovered.

3The medtech validation–reimbursement gap

The healthcare sector contains a structural trap that has swallowed hundreds of millions in development investment. Medical technology companies validate AI for regulatory approval — FDA 510(k) clearance, CE marking — using performance metrics: AUC, sensitivity, specificity on held-out test sets. Reimbursement requires a different and harder evidence standard: clinical utility, cost-effectiveness, and real-world outcomes from actual deployment.

These two evidence frameworks are not aligned. FDA clears a device when it performs as intended without undue risk. CMS and commercial payers cover a service when it improves outcomes, reduces costs, or replaces existing billable procedures. A company can achieve FDA clearance with a rigorous pre-deployment validation study — and that same study provides essentially no reimbursement-qualifying evidence. The data are orthogonal.

The FDA's Total Product Life Cycle framework, updated in January 2025, now requires post-market surveillance as a core quality-system requirement for AI-enabled medical devices — not optional monitoring but mandatory, ongoing documentation of real-world device performance.^[12]This requirement, designed properly, produces precisely the data payers need to support coverage decisions. The tragedy is that almost no medtech company designs its post-market surveillance with reimbursement evidence in mind. They design for regulatory minimum compliance — generating data that answers the regulator's question while systematically failing to answer the payer's.

Companies achieve FDA clearance and then discover they have no reimbursement pathway. The validation strategy served the wrong audience.

4The revenue arithmetic of governance

The NVIDIA 2026 State of AI in Healthcare and Life Sciences survey, drawing on more than 600 professionals, documents what disciplined deployment produces when governance is present: 85% of management-level respondents report AI has increased annual revenue; 80% report reduced operational costs; among those reporting revenue impact, 44% see increases greater than 10%.^[13]

The ROI pattern is specific, not diffuse: medtech companies report the strongest returns in medical imaging (57% reporting ROI there), consistent with post-market surveillance generating real-world outcome data that increasingly supports coverage decisions.^[13]Deloitte's agentic-AI analysis quantifies the gap in enterprise terms: organizations with systematic governance frameworks project cost savings above 20% at a rate of 59%, versus 13% for organizations still watching — a 4.5× difference in expected return.^[3]

The governing principle is not complicated. Governance does not constrain AI value. Governance is the mechanism through which AI value is captured, documented, verified, and translated into revenue-qualifying evidence for payers, defensible documentation for regulators, and auditable records for liability purposes. AI without governance is a performance without a record. In high-consequence sectors, unrecorded performance has no commercial value.

5What best practice looks like: the Constat validation lifecycle

The framework behind Constat was developed in response to the structural problem this paper documents: the gap between what regulatory validation requires and what commercial deployment demands. It addresses five integrated domains that together bridge the regulatory evidence gap and the reimbursement evidence gap simultaneously.

The framework's fundamental insight: most medtech and industrial AI companies build their validation strategy for the regulator and then try to retrofit reimbursement or liability evidence afterward. Retrofitting does not work, because the evidence required for each purpose must be generated prospectively, under conditions that satisfy the evidence standard of the intended audience. Operational proof and runtime monitoring generate the data that serves regulators, payers, and liability documentation simultaneously.

6The reimbursement parallel

Both sectors face an identical evidence disconnection: regulatory compliance does not equal commercial value capture. In healthcare, FDA clearance does not equal CMS reimbursement. In automotive, NHTSA compliance does not equal insurance coverage or favorable underwriting. In both, governance documentation — requirements mapping, operational validation, runtime monitoring — is the bridge between regulatory compliance and commercial value capture.

The $547 billion in failed AI investment in 2025 is not a story about bad models. It is a story about absent governance — and the systematic destruction of value that absence produces.

7Conclusion: governance is the architecture, not the wrapper

In healthcare, the chain of commercial value runs: requirements definition → operational validation in real patient populations → runtime monitoring generating longitudinal outcomes → real-world evidence satisfying payer coverage standards → billable AI-enabled services. Break any link in that chain and the reimbursement pathway closes. The technology can be excellent. The commercial pathway can still be absent.

The 20% of AI projects that are succeeding are not succeeding because they have better models. They are succeeding because they have better governance. The window to establish that architecture as a first-mover advantage is narrowing: CMS's CPT pilots will define which organizations have the evidence to bill; NAIC's Model Bulletin expansion will define which face a structural insurance premium penalty; the EU AI Act's high-risk provisions will define which AI systems have the documentation to remain in European markets. In each case the question is the same: did your organization build AI, or did it build governed AI? The revenue difference between those two answers is now measurable, documented, and growing.

8Postscript: the instrument exists

This paper argues that in high-consequence sectors, unrecorded performance has no commercial value — that every claim must be established from the record. Constat is that argument, productized: a live evidence lifecycle console for FDA AI/ML medical devices in which every extracted field carries a verbatim quote from FDA's own record, every figure is a presence rate with its denominator inline, and premarket evidence, postmarket drift signals, and reimbursement pathways are one connected graph — readable by regulatory teams and queryable by their AI agents over MCP.